Synthesis and Identification of FITC-Insulin Conjugates Produced Using Human Insulin and Insulin Analogues for Biomedical Applications
| Autor: | Dolly Jacob, M. Joan Taylor, Paul Tomlins, Tarsem S. Sahota |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Electrospray Spectrometry Mass Electrospray Ionization Sociology and Political Science medicine.medical_treatment Clinical Biochemistry 02 engineering and technology Mass spectrometry Biochemistry High-performance liquid chromatography 03 medical and health sciences chemistry.chemical_compound Human insulin medicine Phenol Humans Insulin Amino Acid Sequence Fluorescein isothiocyanate Spectroscopy Chromatography High Pressure Liquid Fluorescent Dyes Fluorescent labelling 021001 nanoscience & nanotechnology Flow Cytometry Clinical Psychology 030104 developmental biology Mono-labelled chemistry FITC-insulin HPLC 0210 nano-technology Law Social Sciences (miscellaneous) Fluorescein-5-isothiocyanate Conjugate |
| Zdroj: | Journal of fluorescence. 26(2) |
| ISSN: | 1573-4994 |
| Popis: | We thank EPSRC National Mass Spectrometry Facility, Swansea University for their help with FITC-insulin analysis. fluorescein isothiocyanate (FITC) and the conjugate species produced were identified using high performance liquid chromatography and electrospray mass spectroscopy. Mono-labelled FITC-insulin conjugate (A1 or B1) was successfully produced using human insulin at short reaction times (up to 5 h) however the product always contained some unlabelled native human insulin. As the reaction time was increased over 45 h, no unlabelled native human insulin was present and more di-labelled FITC-insulin conjugate (A1B1) was produced than mono-labelled conjugate with the appearance of tri-labelled conjugate (A1B1B29) after 20 h reaction time. The quantities switch from mono-labelled to di-labelled FITC-insulin conjugate between reaction times 9 and 20 h. In the presence of phenol or m-cresol, there appears to be a 10 % decrease in the amount of mono-labelled conjugate and an increase in di-labelled conjugate produced at lower reaction times. Clinically used insulin analogues present in commercially available preparations were successfully fluorescently labelled for future biomedical applications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink